Get the Stockscreener App
34.47
0.67%
0.23
Definium Therapeutics Inc stock is traded at $34.47, with a volume of 739.62K.
It is up +0.67% in the last 24 hours and down -6.38% over the past month.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
See More
Previous Close:
$34.24
Open:
$34.23
24h Volume:
739.62K
Relative Volume:
0.35
Market Cap:
$4.63B
Revenue:
Net Income/Loss:
$-237.54M
P/E Ratio:
-13.77
EPS:
-2.5033
Net Cash Flow:
$-145.05M
1W Performance:
+0.85%
1M Performance:
-6.38%
6M Performance:
+55.62%
1Y Performance:
+0.00%
1-Day Range:
$33.92
$34.79
1-Week Range:
$33.65
$38.04
52-Week Range:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
34.47 | 4.63B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-26 | Initiated | JP Morgan | Overweight |
| Aug-18-26 | Initiated | BofA Securities | Buy |
| Jul-27-26 | Initiated | Wells Fargo | Overweight |
| Jun-23-26 | Reiterated | Needham | Buy |
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-10-26 | Initiated | Piper Sandler | Overweight |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (DFTX) Latest News
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Definium Therapeutics Insider Sold Shares Worth $1,153,784, According to a Recent SEC Filing - Yahoo Finance
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CMO Daniel Karlin sells $396,894 in stock - Investing.com
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares - Investing.com
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares By Investing.com - Investing.com Nigeria
Definium Therapeutics CCO Matthew Wiley sells $113,257 in common shares By Investing.com - Investing.com Nigeria
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares By Investing.com - Investing.com UK
Definium Therapeutics CMO Daniel Karlin sells $396,894 in stock By Investing.com - Investing.com UK
Definium Therapeutics CCO Matthew Wiley sells $113,257 in common shares - Investing.com
Definium Therapeutics CLO Mark Sullivan sells $513,845 in shares - Investing.com
Definium therapeutics CFO Brandi Roberts sells $123,496 in shares - Investing.com
To cover taxes, Definium Therapeutics (DFTX) medical chief sells 10,853 shares. - Stock Titan
To cover taxes on vested stock grants, Definium Therapeutics (DFTX) CEO sold 31,550 shares. - Stock Titan
To cover vesting taxes, Definium Therapeutics (DFTX) officer sells 3,097 shares. - Stock Titan
To cover stock-grant taxes, Definium Therapeutics (DFTX) legal chief sells 14,051 shares. - Stock Titan
To cover vesting taxes, Definium Therapeutics (DFTX) CFO sells 3,377 shares. - Stock Titan
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
An officer sold 2,867 shares in the prior three months and lists 3,097 for sale at Definium Therapeutics (DFTX). - Stock Titan
After selling 3,013 shares in June, a Definium Therapeutics (DFTX) officer proposes selling 3,377. - Stock Titan
After selling 13,008 shares in June, Definium Therapeutics (DFTX) officer Mark Sullivan proposes to sell 14,051. - Stock Titan
After selling 10,035 shares in June, a Definium Therapeutics (DFTX) officer proposes another sale. - Stock Titan
Director at Definium Therapeutics (DFTX) now holds 22,296 shares - Stock Titan
Director boosts Definium (DFTX) stake with option exercise - Stock Titan
Definium Therapeutics (NasdaqGS:DFTX) Stock Forecast & Analyst Predictions - Simply Wall Street
Definium (DFTX) CEO awarded 750,000 shares tied to clinical milestones - Stock Titan
Definium Therapeutics (DFTX) grants CFO 125,000 stock units tied to milestones - Stock Titan
Definium (DFTX) legal chief now holds 508K shares - Stock Titan
Definium Therapeutics (DFTX) awards 125K performance shares tied to 2028 milestones - Stock Titan
Equity grant lifts Definium Therapeutics (DFTX) CMO stake to 803,699 shares - Stock Titan
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Definium Therapeutics' Upcoming Phase 3 Data on DT120 to De-Risk Program, Back FDA Approval, RBC Says - marketscreener.com
DFTX Reiterated by RBC Capital -- Price Target Maintained at $66.00 - GuruFocus
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - BioSpace
Definium Therapeutics (DFTX) Showcases Phase 3 Data Amid High Va - GuruFocus
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - Yahoo Finance
DFTXDefinium Therapeutics Inc Revenue Breakdown - Finviz
Definium Therapeutics CEO Robert Barrow Sells 19,023 Shares Following 40,000-Share Award - Kalkine Media
Definium Therapeutics Secures Second FDA Breakthrough Therapy Designation for DT120 in MDD - Minichart
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com Nigeria
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com UK
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics Inc Stock (DFTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Definium Therapeutics Inc Stock (DFTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer |
Sep 25 '26 |
Sale |
36.57 |
31,550 |
1,153,784 |
2,213,090 |
| BRANDI ROBERTS | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
3,377 |
124,037 |
0 |
| MATTHEW THOMAS WILEY | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
3,097 |
113,753 |
0 |
| DANIEL ROLLINGS KARLIN | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
10,853 |
398,631 |
0 |
| ROBERT B BARROW | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
31,550 |
1,158,832 |
0 |
| MARK SULLIVAN | Officer |
Sep 25 '26 |
Proposed Sale |
36.73 |
14,051 |
516,093 |
0 |
| Roberts Brandi | Chief Financial Officer |
Sep 25 '26 |
Sale |
36.57 |
3,377 |
123,497 |
394,528 |
| Sullivan Mark | Chief Legal Officer |
Sep 25 '26 |
Sale |
36.57 |
14,051 |
513,845 |
494,228 |
| Wiley Matthew T. | Chief Commercial Officer |
Sep 25 '26 |
Sale |
36.57 |
3,097 |
113,257 |
359,036 |
| Vallone Carol A | Director |
Sep 18 '26 |
Option Exercise |
35.52 |
1,086 |
38,575 |
22,296 |
0.79%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):